Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its generic version of GE Healthcare’s Vizamyl (flutemetamol F-18). This trial aims to evaluate the positron emission tomography (PET) imaging of neuroinflammatory plaque density in the brains of adult patients with cognitive impairment. Such impairment can be attributed to Alzheimer’s disease (AD) or other causes.
Vizamyl, a radioactive diagnostic agent designed for PET brain imaging, was granted approval in the US in October 2013. However, it has not yet been filed for marketing in China. This development signifies a step forward in potentially bringing a much-needed diagnostic tool to the Chinese market.- Flcube.com
